67.65MMarket Cap-1.03P/E (TTM)
0.9500High0.9000Low59.62KVolume0.9058Open0.9084Pre Close54.97KTurnover0.25%Turnover RatioLossP/E (Static)75.00MShares2.750052wk High0.81P/B21.87MFloat Cap0.899952wk Low--Dividend TTM24.25MShs Float10.8700Historical High--Div YieldTTM5.50%Amplitude0.4700Historical Low0.9210Avg Price1Lot Size
Context Therapeutics Stock Forum
📊⚡️📊
CTIM-76's development targets a significant unmet need in CLDN6-positive cancers. The bispecific antibody's mechanism of action, engaging T cells to target CLDN6-expressing tumor cells, represents a sophisticated approach in immuno-oncology. Recent SITC presentation data supporting the first-in-human dose selection indicates robust preclinical validation.
For investors, thi...
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Tuesday, 14th January at 4:58 pm
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers
Trial marks key milestone in driving pipeline progress
PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today anno...
📊⚡️📊
No comment yet